Cargando…

The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer

BACKGROUND: Breast cancer is the most common cancer worldwide, and triple-negative breast cancer (TNBC) has the worst prognosis. Standard systemic treatment includes chemotherapy and immunotherapy. Poly ADP-ribose polymerase (PARP) inhibitors are considered in breast cancer (BRCA) susceptibility gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jing, Zhang, Dianbao, Liu, Zhiwei, Wang, Yukun, Li, Xinyang, Wang, Ziming, Liang, Gaofeng, Yuan, Xiang, Li, Yuanpei, Komorowski, Andrzej L., Rozen, Warren Matthew, Orlandi, Armando, Takabe, Kazuaki, Franceschini, Gianluca, Jerusalem, Guy, Wang, Xinshuai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929791/ https://www.ncbi.nlm.nih.gov/pubmed/36819490 http://dx.doi.org/10.21037/atm-22-6446

Ejemplares similares

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials
por: Wang, Yukun, et al.
Publicado: (2020)

MiR-16-5p suppresses breast cancer proliferation by targeting ANLN
por: Wang, Ziming, et al.
Publicado: (2021)

Bioinformatics analysis on enrichment analysis of potential hub genes in breast cancer
por: Wei, Limin, et al.
Publicado: (2021)

Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer
por: Chen, Jing, et al.
Publicado: (2021)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer
por: Katsuta, Eriko, et al.
Publicado: (2021)

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
por: Wang, Xuan, et al.
Publicado: (2020)

The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study
por: Liu, Zhiyong, et al.
Publicado: (2023)

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2023)

CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients
por: Oshi, Masanori, et al.
Publicado: (2020)

Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment
por: Gandhi, Shipra, et al.
Publicado: (2021)

PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis
por: Li, Han, et al.
Publicado: (2023)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach
por: Orlandi, Paola, et al.
Publicado: (2021)

Polyethyleneimine-coated quantum dots for miRNA delivery and its enhanced suppression in HepG2 cells
por: Liang, Gaofeng, et al.
Publicado: (2016)

Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival
por: Oshi, Masanori, et al.
Publicado: (2021)

Racial and ethnic disparities in breast cancer survival: critical appraisal of the data emerging from the randomized TAILORx
por: Franceschini, Gianluca, et al.
Publicado: (2022)

PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma
por: Su, Ke, et al.
Publicado: (2022)

Enhanced Antibacterial and Anti-Biofilm Activities of Antimicrobial Peptides Modified Silver Nanoparticles
por: Xu, Juanjuan, et al.
Publicado: (2021)

Antiangiogenic Polyketides from Peperomia dindygulensis Miq
por: Wang, Qi-Wei, et al.
Publicado: (2012)

High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer
por: Katsuta, Eriko, et al.
Publicado: (2019)

A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2021)

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

Antiangiogenic Therapy for Glioma
por: Cea, Valentina, et al.
Publicado: (2012)

Antiangiogenic Cancer Therapy
por: Maxwell, P H, et al.
Publicado: (2009)

Antiangiogenic effects of oridonin
por: Tian, Lili, et al.
Publicado: (2017)

Antiangiogenic Effect of Alkaloids
por: Alasvand, Masoud, et al.
Publicado: (2019)

Antiangiogeneic Strategies in Mesothelioma
por: Nowak, Anna K., et al.
Publicado: (2020)

47982 Reversing the resistance to chemotherapy in White and Black patients with triple negative breast cancer (TNBC).
por: Gandhi, Shipra, et al.
Publicado: (2021)

Mechano-Sensing Channel PIEZO2 Enhances Invasive Phenotype in Triple-Negative Breast Cancer
por: Katsuta, Eriko, et al.
Publicado: (2022)

“Targeting Design” of Nanoparticles in Tumor Therapy
por: Yang, Tingting, et al.
Publicado: (2022)

Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Synthesis and Antiangiogenic Activity of Novel Gambogic Acid Derivatives
por: Chen, Tao, et al.
Publicado: (2012)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review
por: Wang, Chaokun, et al.
Publicado: (2020)

Antiangiogenic drugs in ovarian cancer
por: Kumaran, G C, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_lnnsjqv2kb27imhs4kvmulnckd